Table 4.

Spearman correlations between baseline or change in serum MMP-3 levels and clinical assessments after 3 and 12 months of etanercept treatment.

Baseline Δ0–3/12 BASDAIBaseline Δ0–3/12 ESRBaseline Δ0–3/12 CRPBaseline Δ0–3/12 ASDASBaseline Δ0–3/12 PhyGDABaseline Δ0–3/12 PatGDABaseline Δ0–3/12 BASFI
Males (n = 68)
  Baseline MMP-3ρ−0.1640.0860.163−0.0160.173−0.122−0.050
p0.1900.4950.1940.8980.1720.3340.695
  Δ0–3 MMP-3ρ0.4100.3460.3590.5400.2640.3190.250
p0.0010.0080.0060.0000.0470.0150.058
  Δ0–12 MMP-3ρ0.3190.3430.3940.3300.3280.2770.251
p0.0180.0130.0030.0150.0150.0410.065
Females (n = 24)
  Baseline MMP-3ρ−0.0270.3700.6390.492−0.065−0.2170.076
p0.9050.0900.0010.0230.7740.3460.738
  Δ0–3 MMP-3ρ0.2980.2360.2610.3970.4920.3400.276
p0.2290.3470.2960.1150.0380.1820.268
  Δ0–12 MMP-3ρ0.5610.0980.6020.7000.4440.4020.549
p0.0370.7270.0180.0040.1120.1380.034
  • Δ0–3: baseline to 3 months change; Δ0–12: baseline to 12 months change; PhyGDA: physician global disease activity; PatGDA: patient global disease activity. See Table 1 for other definitions.